DEBRA KIME: Open Payments
NPI 1114982709 · MACON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,592 in 74 payments from 16 companies in 2025. Trend: 2023 $704 · 2024 $1,017 · 2025 $1,592
Food & beverage: $1,581Education: $10
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $368 |
| ABBVIE INC. | 18 | $320 |
| Janssen Biotech, Inc. | 11 | $221 |
| Gilead Sciences, Inc. | 8 | $160 |
| Medtronic, Inc. | 3 | $152 |
| Ardelyx, Inc. | 6 | $96 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 2 | $58 |
| EVOKE PHARMA, INC. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
Products named: ENTYVIO, TREMFYA, RINVOQ, INTERSTIM, IBSRELA, SKYRIZI, XIFAXAN, DUPIXENT.
Industry payments across GA — which companies pay providers there.
